Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV
-
By
-
Jose F. Figueroa
-
Rebekah I. Stein
-
Jessica Phelan
-
E. John Orav
-
Grace Luu
-
Shibani S. Mukerji
-
Emily P. Hyle
-
June 12, 2026
-
Clinical Scorecard: Injectable Long-Lasting Antiretroviral Therapy for HIV Patients Enrolled in Medicare
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Long-acting injectable antiretroviral therapy (LA-ART) provides sustained viral suppression without daily pill adherence, approved by the FDA in 2021. |
| Target Population | |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- I
- n
- c
- l
- u
- d
- e
-
- s
- p
- e
- c
- i
- f
- i
- c
-
- e
- x
- a
- m
- p
- l
- e
- s
-
- o
- f
-
- p
- o
- t
- e
- n
- t
- i
- a
- l
-
- d
- r
- u
- g
- -
- d
- r
- u
- g
-
- i
- n
- t
- e
- r
- a
- c
- t
- i
- o
- n
- s
-
- t
- o
-
- m
- o
- n
- i
- t
- o
- r
- .
Risks
Patient & Prescribing Data
Medicare beneficiaries with HIV enrolled in Parts B and D.
Uptake of LA-ART is low, with significant disparities based on age, race, and chronic conditions.
Clinical Best Practices
- additional_recommendation
Related Resources & Content
